|
|
|
| home > news > detailed info |
|
|
 INDUSTRY NEWS AND PRESS RELEASES |
Bavarian Nordic Secures Vaccine Order From European Country After Confirmed Monkeypox Cases |
 |
|
COPENHAGEN, Denmark, May 19, 2022 – Bavarian Nordic A/S (OMX: BAVA) announced today that the Company has secured a contract with an undisclosed European country to supply its IMVANEX® smallpox vaccine in response to new cases of monkeypox evolving during May 2022.
The first European case was confirmed on May 7, 2022, in an individual who returned from a travel to Nigeria, where monkeypox is endemic. Subsequently, more than 20 cases have been confirmed across England, Portugal and Spain with additional suspected cases currently being investigated. Evidence points to that most of the infections have been acquired locally in these countries. In the US, a single case has been confirmed in a traveler from Canada, where no cases are yet confirmed, but several remain under investigation.
Bavarian Nordic’s smallpox vaccine is approved in the U.S. as JYNNEOS® and in Canada as IMVAMUNE®, both places with the approval extended to cover the monkeypox indication. The vaccine is approved in Europe as IMVANEX® for only the smallpox indication but has previously been provided for off-label use in response to monkeypox cases.
Paul Chaplin, President and CEO of Bavarian Nordic said: “While the full circumstances around the current monkeypox cases in Europe remain to be elucidated, the speed of which these have evolved, combined with the potential for infections beyond the initial case going undetected, calls for a rapid and coordinated approach by the health authorities, and we are pleased to assist in this emergency situation. Infection control has been a high priority for societies during COVID-19, and this situation is an unfortunate reminder, that we cannot let our guard down, but must continue to build and strengthen our infectious disease preparedness to keep the world open.”
This order has no impact on the Company’s financial guidance for 2022.
About monkeypox
Monkeypox is a rare, but serious disease, which is endemic in Central and West Africa. The disease is quite similar to human smallpox, although it is less severe with an estimated fatality rate of 1-10%.
|
|
|
|
|
|
 |
|
|
 |
News and Press Releases |
 |
Productive Networking Of Pharmaceutical Leaders At PHARMAP 2022
Connecting innovators in the pharmaceutical industry and contributing to
further development of ongoing pharmaceutical trends were the main
directions of PHARMAP 2022. The Congress gathered pharmaceutical
companies, CMOs and CDMOs, governmental bodies together with
pharmaceutical equipment providers and service companies to exchange
experience in digital transformation and discuss innovative solutions
and business practices. The Congress was held on June, 20-21, 2022 in
Berlin, Germany.
More info >> |
|
 |
White Papers |
 |
|
 |
Industry Events |
 |
Connect in Pharma
14-15 September 2022, Plaexpo, Geneva, Switzerland
The new event driving innovation for pharma and biopharma businesses,
Connect in Pharma will unite key players in Pharmaceutical and
Biopharmaceutical packaging and production in Geneva on 14 – 15
September 2022.
More info >> |
|
|
